Leslie BENET    SITE

  • AAPS J. 2021;23:67. There is only one valid definition of clearance: Critical examination of clearance concepts reveals the potential for errors in clinical drug dosing decisions. Benet LZ, Sodhi JK, Makrygiorgos G, Mesbah A. PubMed
  • Clin Pharmacol Ther. 2021;110:480-485. The effects of single dose Rifampin on the pharmacokinetics of Fluvastatin in healthy volunteers. Xiang Y, Okochi H, Kozachenko I, Sodhi JK, Frassetto LA, Benet LZ. PubMed
  • Pharm Res. 2021;38:795-801. Investigating intestinal transporter involvement in Rivaroxaban disposition through examination of changes in absorption. Kou W, Sodhi JK, Wu X, Benet LZ. PubMed
  • Pharm Res. 2020;37:208. Intestinal efflux transporters P-gp and BCRP are not clinically relevant in Apixaban disposition. Sodhi JK, Liu S, Benet LZ. PubMed
  • AAPS J. 2020;22:120. Investigating the theoretical basis for in vitro-in vivo extrapolation (IVIVE) in predicting drug metabolic clearance and proposing future experimental pathways. Benet LZ, Sodhi JK. PubMed
  • AAPS J. 2020;22:111. The necessity of using changes in absorption time to implicate intestinal transporter involvement in oral Drug-Drug Interactions. Sodhi JK, Benet LZ. PubMed
  • Chem Med Chem. 2020;15:1862-1874. The critical role of passive permeability in designing successful drugs. Di L, Artursson P, Avdeef A, Benet LZ, Houston JB, Kansy M, Kerns EH, Lennernäs H, Smith DA, Sugano K. PubMed
  • Clin Pharmacokinet. 2020 Jul 28:1-18. Volume of distribution is unaffected by metabolic Drug-Drug Interactions. Sodhi JK, Huang CH, Benet LZ. PubMed
  • Drug Metab Dispos. 2020;48:537-543. Are there any experimental perfusion data that preferentially support the dispersion and parallel-tube models over the well-stirred model of organ elimination? Sodhi JK, Wang HJ, Benet LZ. PubMed
  • Pharm Res. 2020;37:73. Challenging the relevance of unbound tissue-to-blood partition coefficient (Kpuu) on prediction of Drug-Drug Interactions. Sodhi JK, Liu S, Benet LZ. PubMed
  • Clin Pharmacol Ther. 2020:In press. A simple methodology to differentiate changes in bioavailability from changes in clearance following oral dosing of metabolized drugs. Sodhi JK, Benet LZ. PubMed
  • Pharmacotherapy. 2020;40:274-290. Predicting interactions between Rifampin and antihypertensive drugs using the Biopharmaceutics Drug Disposition Classification System. Liu W, Yan T, Chen K, Yang L, Benet LZ, Zhai S. PubMed
  • Pharmacology. 2020;105:145-163. Late-Stage Failures of Monoclonal Antibody Drugs: A Retrospective Case Study Analysis. Sun A, Benet LZ. doi: 10.1159/000505379. Epub 2020 Jan 7. PMID: 31910414. PubMed
  • Drug Discov Today. 2019;24:2299-2306. Can BDDCS illuminate targets in drug design? Bocci G, Benet LZ, Oprea TI. PubMed
  • Drug Metab Dispos. 2019;47:1397-1402. Protein binding and hepatic clearance: Re-examining the discrimination between models of hepatic clearance with Diazepam in the isolated perfused rat liver preparation. Wang HJ, Benet LZ. PubMed
  • Drug Metab Dispos. 2019;47:1368-1371. In vitro-in vivo inaccuracy: The CYP3A4 Anomaly. Bowman CM, Benet LZ. PubMed
  • Pharm Res. 2019;36:155. Food, acid supplementation and drug absorption - a complicated gastric mix: a randomized control trial. Surofchy DD, Frassetto LA, Benet LZ. PubMed
  • AAPS J. 2019;21:103. How transporters have changed basic pharmacokinetic understanding. Benet L1, Bowman CM, Sodhi JK. PubMed
  • Drug Metab Dispos. 2019;47:1004-1012. The enhancement of subcutaneous first-pass metabolism causes non-linear pharmacokinetics of TAK-448 after a single subcutaneous administration to rats. Moriya Y, Kogame A, Tagawa Y, Morohashi A, Kondo T, Asahi S, Benet LZ. PubMed
  • Pharm Res. 2019;36:113. Interlaboratory variability in human hepatocyte intrinsic clearance values and trends with physicochemical properties. Bowman CM, Benet LZ. PubMed
  • J Pharmacokinet Pharmacodyn. 2019;46:155-163. Understanding drug-drug interaction and pharmacogenomic changes in pharmacokinetics for metabolized drugs. Benet LZ, Bowman CM, Koleske ML, Rinaldi CL, Sodhi JK. PubMed
  • J Pharm Sci. 2019. pii: S0022-3549(19)30094-2. In vitro-in vivo extrapolation and hepatic clearance-dependent underprediction. Bowman CM, Benet LZ. PubMed
  • Drug Metab Dispos. 2019;47:525-534. Characterization of fasiglifam-related liver toxicity in dogs. Kogame A, Moriya Y, Mori I, Pan L, Morohashi A, Ebihara T, Fukui H, Tagawa Y, Benet LZ. PubMed
  • Drug Metab Dispos. 2019;47:358-363 The presence of a transporter-induced protein binding shift: a new explanation for protein-facilitated uptake and improvement for in vitro-in vivo extrapolation. Bowman CM, Okochi H, Benet LZ. PubMed
  • Eur J Pharm Sci. 2018;123:502-514. An examination of protein binding and protein-facilitated uptake relating to in vitro-in vivo extrapolation. Bowman CM, Benet LZ. PubMed
  • Clin Pharmacol Ther. 2019;105:326-328. Batch-to-batch and within-subject variability: What do we know and how do these variabilities affect clinical pharmacology and bioequivalence? Benet LZ, Jayachandran P, Carroll KJ, Burmeister Getz E. PubMed
  • Clin Pharmacol Ther. 2019;10:411-416. Evaluating within-subject variability for narrow therapeutic index drugs. Jayachandran P, Okochi H, Frassetto LA, Park W, Fang L, Zhao L, Benet LZ. PubMed
  • Pharm Res. 2018;35:242. The extended clearance concept following oral and intravenous dosing: Theory and critical analyses. Benet LZ, Bowman CM, Liu S, Sodhi JK. PubMed
  • Toxicol Res (Camb). 2018;7:358-370. Evaluation of the relevance of DILI predictive hypotheses in early drug development: Review of in vitro methodologies vs BDDCS classification. Chan R, Benet LZ. PubMed
  • J Clin Pharmacol. 2018;58:979-989. Predicting pharmacokinetics/pharmacodynamics in the individual patient: separating reality from hype. Benet LZ. PubMed
  • Clin Ther. 2018;40:660-662. A drug-drug interaction between Cyclosporine and Nystatin. Liu W, Guan X, Yu Z, Chen K, Benet L, Zhai S. PubMed
  • AAPS J. 2018;20:46. Why drugs fail in late stages of development: Case study analyses from the last decade and recommendations. Parasrampuria DA, Benet LZ, Sharma A. PubMed
  • Toxicol Sci. 2018;162:499-508. Measures of BSEP inhibition in vitro are not useful predictors of DILI. Chan R, Benet LZ. PubMed
  • J Pharm Sci. 2017;106:2231-2233. Understanding the potential interethnic difference in Rosuvastatin pharmacokinetics. Benet LZ, Wu HF. PubMed
  • J Pharm Sci. 2017;106:2895-2898. Cellular uptake of Levocetirizine by Organic Anion Transporter 4. Noguchi S, Nishimura T, Mukaida S, Benet LZ, Nakashima E, Tomi M. PubMed
  • J Pharm Sci. 2017;106:2751-2757. Rosuvastatin pharmacokinetics in Asian and White Subjects Wild Type for Both OATP1B1 and BCRP Under Control and Inhibited Conditions. Wu HF, Hristeva N, Chang J, Liang X, Li R, Frassetto L, Benet LZ. PubMed
  • Chin J Nat Med. 2016;14:888-897. Classification of natural products as sources of drugs according to the biopharmaceutics drug disposition classification system (BDDCS). Li J, Larregieu CA, Benet LZ. PubMed
  • Drug Metab Dispos. 2016;44:1731-1735. Hepatic clearance predictions from in vitro-in vivo extrapolation and the Biopharmaceutics Drug Disposition Classification System. Bowman CM, Benet LZ. PubMed
  • Clin Pharmacokinet. 2016;55:143-67. Reliability of in vitro and in vivo methods for predicting the effect of P-Glycoprotein on the delivery of antidepressants to the brain. Zheng Y, Chen X, Benet LZ. PubMed
  • J Pharm Sci. 2015;104:3229-35. Few drugs display Flip-Flop pharmacokinetics and these are primarily associated with classes 3 and 4 of the BDDCS. Garrison KL, Sahin S, Benet LZ. PubMed
  • Pharm Res. 2015;32:2516-26. pH dependent but not P-gp dependent bidirectional transport study of S-propranolol: the importance of passive diffusion. Zheng Y, Benet LZ, Okochi H, Chen X. PubMed
  • AAPS J. 2014;16:1085-96. Predicting when biliary excretion of parent drug is a major route of elimination in humans. Hosey CM, Broccatelli F, Benet LZ. PubMed
  • Mol Pharm. 2014;11:1335-44. Distinguishing between the permeability relationships with absorption and metabolism to improve BCS and BDDCS predictions in early drug discovery. Larregieu CA, Benet LZ. PubMed
  • Mol Pharm. 2013;10:4038-45. Effect of P-glycoprotein on the rat intestinal permeability and metabolism of the BDDCS class 1 drug verapamil. Estudante M, Maya M, Morais JG, Soveral G, Benet LZ. PubMed
  • Clin Pharmacol Ther. 2012;92:551-2. A step closer to personalized chemotherapy: consideration of the influence of genetic variation in hepatic uptake transporters on the metabolism of CYP3A substrates. Benet LZ. PubMed
  • Adv Drug Deliv Rev. 2013;65:1340-56. Intestinal drug transporters: an overview. Estudante M, Morais JG, Soveral G, Benet LZ. PubMed
  • Pharm Res. 2012;29:1768-74. Sotalol permeability in cultured-cell, rat intestine, and PAMPA system. Liu W, Okochi H, Benet LZ, Zhai SD. PubMed
  • Adv Drug Deliv Rev. 2012;64:95-109. Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Broccatelli F, Larregieu CA, Cruciani G, Oprea TI, Benet LZ. PubMed
  • Mol Pharm. 2012;9:570-80. BDDCS class prediction for new molecular entities. Broccatelli F, Cruciani G, Benet LZ, Oprea TI. PubMed
  • J Pharm Sci. 2011;100:4047-9. Lead PK commentary: predicting human pharmacokinetics. Rowland M, Benet LZ. PubMed
  • J Pharm Sci. 2011;100:3831-42. Effects of uremic toxins on transport and metabolism of different biopharmaceutics drug disposition classification system xenobiotics. Reyes M, Benet LZ. PubMed
  • J Pharmacokinet Pharmacodyn. 2010;37:529-39. Clearance (née Rowland) concepts: a downdate and an update. Benet LZ. PubMed
  • Clin Pharmacol Ther. 2010;88:540-7. Effect of single-dose rifampin on the pharmacokinetics of warfarin in healthy volunteers. Frymoyer A, Shugarts S, Browne M, Wu AH, Frassetto L, Benet LZ. PubMed
  • Nat Rev Drug Discov. 2010;9:215-36. Membrane transporters in drug development. International Transporter Consortium, Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L. PubMed
  • Basic Clin Pharmacol Toxicol. 2010;106:162-7. Predicting drug disposition via application of a Biopharmaceutics Drug Disposition Classification System. Benet LZ. PubMed
  • Mol Pharm. 2009;6:1631-43. The drug transporter-metabolism alliance: uncovering and defining the interplay. Benet LZ. PubMed
  • Pharm Res. 2009;26:2039-54. The role of transporters in the pharmacokinetics of orally administered drugs. Shugarts S, Benet L. PubMed
  • J Pharm Sci. 2009;98:4413-9. Comparison of bidirectional lamivudine and zidovudine transport using MDCK, MDCK-MDR1, and Caco-2 cell monolayers. de Souza J, Benet LZ, Huang Y, Storpirtis S. PubMed
  • AAPS J. 2009;11:250-61. Effects of drug transporters on volume of distribution. Grover A, Benet LZ. PubMed
  • Clin Pharmacol Ther. 2009;85:78-85. Elucidating rifampin's inducing and inhibiting effects on glyburide pharmacokinetics and blood glucose in healthy volunteers: unmasking the differential effects of enzyme induction and transporter inhibition for a drug and its primary metabolite. Zheng HX, Huang Y, Frassetto LA, Benet LZ. PubMed
  • Adv Drug Deliv Rev. 2008;60:717-33. Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. Custodio JM, Wu CY, Benet LZ. PubMed
  • Clin Pharmacol Ther. 2007;81:194-204. Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Lau YY, Huang Y, Frassetto L, Benet LZ. PubMed

PubMed

San Francisco, US

BENET LESLIE.jpg

Last update: October 2021